Latest on Anabolic Agents for Osteoporosis Treatment

Document Type

Article

Publication Date

9-26-2024

Institution/Department

Center for Clinical & Translational Science

Journal Title

Endocrinology and metabolism clinics of North America

MeSH Headings

Humans; Osteoporosis (drug therapy); Anabolic Agents (therapeutic use, adverse effects); Bone Density Conservation Agents (therapeutic use); Teriparatide (therapeutic use); Osteoporotic Fractures (prevention & control); Antibodies, Monoclonal; Parathyroid Hormone-Related Protein

Abstract

In the last decades, novel therapeutics with anabolic bone properties have been developed and are currently used in the management of osteoporosis particularly in patients with high-risk of fragility fractures. These drugs include PTH-Related Analogues, teriparatide and abaloparatide, and the anti-sclerostin agent romosozumab, this latter drug currently approved only in female patients. Their efficacies in preventing fragility fractures are widely demonstrated and their potential serious side effects were progressively downgraded, including risk of malignancies in teriparatide- and cardiovascular events in romosozumab-users, respectively. Further data are warranted about their efficacy in glucocorticoids-induces osteoporosis and fracture healings.

First Page

513

Last Page

523

Link to Full Text

Share

COinS